CRISPR Therapeutics AG/ CH0334081137 /
| 2024-05-03 9:59:40 PM | Chg. +0.87 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 55.92USD | +1.58% | 16,612 Turnover: 936,663.46 |
-Bid Size: - | -Ask Size: - | 4.49 bill.USD | - | - |
Fundamentals
| FY 2023 | Growth (1Y) | |
|---|---|---|
| Per Share | ||
| Earnings per Share: | -1.94 USD | -76.79% |
| EPS Diluted: | - USD | -76.79% |
| Revenues per Share: | 4.62 USD | 30,256.60% |
| Book Value per Share: | 23.45 USD | -1.65% |
| Cash Flow per Share: | -3.24 USD | -48.54% |
| Dividend per Share: | - USD | - |
| Total | in mill. | |
| Revenues: | 371.21 USD | 30,885.48% |
| Net Income: | -153.61 USD | -76.37% |
| Operating Cash Flow: | -260.38 USD | - |
| Cash and Cash Equivalents: | 389.48 USD | - |
Valuation Ratios
| Current | Latest FY* | |
|---|---|---|
| P/E Ratio: | - | - |
| P/S Ratio: | 12.09 | 13.54 |
| P/BV ratio: | 2.38 | 2.67 |
| P/CF Ratio: | -17.23 | -19.30 |
| PEG: | 0.38 | - |
| Earnings Yield: | -3.47% | -3.10% |
| Dividend Yield: | - | - |
| Market Capitalization | ||
| Market Capitalization: | 4.49 bill. USD | 5.03 bill. USD |
| Free Float Market Cap.: | - USD | - USD |
| Market Cap. / Employee: | - USD | - USD |
| Shares Outstanding: | 80.28 mill. | |
Profitability
| Gross Profit Margin: | - |
| EBIT Margin: | -59.95% |
| Net Profit Margin: | -41.38% |
| Return on Equity: | -8.16% |
| Return on Assets: | -6.89% |
Financial Strength
| Liquidity I / Cash Ratio: | 358.00% |
| Liquidity II / Quick Ratio: | 541.84% |
| Liquidity III / Current Ratio: | 1,753.89% |
| Debt / Equity Ratio: | 18.42% |
| Dynam. Debt / Equity Ratio: | -133.18% |
Efficiency
| Employees: | - |
| Personal Expenses / Employee: | - USD |
| Revenues / Employee: | - USD |
| Net Income / Employee: | - USD |
| Total Assets / Employee: | - USD |
| * Fiscal Year End: | 2023-12-31 |
| Accounting Standard: | US GAAP |
| Currency: | USD |
